Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo

Tel:  +47 21 07 81 60

New search    Hide text from Guidelines


Antiinfectives are also classified in the following groups:

A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S03 Eye and ear preparations with antiinfectives

Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use

Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).


This group comprises antibacterials for systemic use, except antimycobacterials, which are classified in J04. The antibacterials are classified according to their mode of action and chemistry.

Combinations of two or more systemic antibacterials from different third levels are classified in J01R, except combinations of sulfonamides and trimethoprim, which are classified at a separate 4th level, J01EE.

Combinations of antibacterials and tuberculostatics are classified in J04AM.

Combinations of antibacterials with other drugs, including local anesthetics or vitamins, are classified at separate 5th levels in the respective antibacterial group by using the 50-series.

Inhaled antiinfectives are classified here based on the fact that preparations for inhalation can not be separated from preparations for injection.


This group comprises systemic sulfonamide and trimethoprim preparations. Combinations of sulfonamide and trimethoprim are classified in J01EE. Preparations containing two or more sulfonamides are classified within the different 4th levels, using the 5th level code 20.

In such combinations, the half-life of the most long-acting sulfonamide determines the classification. Sulfonamides in combinations with other antibacterials (excl. trimethoprim) are classified in J01R. Dapsone is classified in J04 - Antimycobacterials. See also A07A - Intestinal antiinfectives.

Preparations, which in addition contain a urine acidifier, such as vitamin C, calcium- or ammonium chloride, are classified at the plain 5th levels.

The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.

J01EA Trimethoprim and derivatives

The DDDs are based on the treatment of acute urinary-tract infections.

J01EB Short-acting sulfonamides

This group comprises sulfonamides with a biological half-life not exceeding approx. 7 hours.

J01EC Intermediate-acting sulfonamides

This group comprises sulfonamides with a biological half-life of approx.
11-12 hours.

J01ED Long-acting sulfonamides

This group comprises sulfonamides with a biological half-life of approx.
35 hours or more.

J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives

When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.

Last updated: 2018-12-13